Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05061550
Title Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors AstraZeneca

lung non-small cell carcinoma


Durvalumab + Monalizumab

Durvalumab + Oleclumab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN

Additional content available in CKB BOOST